Nanobiotix S.A. Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
Nanobiotix S.A. (NNBXF) reported Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of EUR 3.54 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2026-03-31
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 6 month | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | 3.54M EUR 20-F · filed 2026-03-31 | ||
| 2025-06-30 | 2.16M EUR 6-K · filed 2025-09-30 | ||
| 2024-12-31 | 4.30M EUR 20-F · filed 2026-03-31 | ||
| 2024-06-30 | 1.94M EUR 6-K · filed 2025-09-30 | ||
| 2023-12-31 | 3.22M EUR 20-F · filed 2026-03-31 | ||
| 2023-06-30 | 1.35M EUR 6-K · filed 2024-09-18 | ||
| 2022-12-31 | 3.17M EUR 20-F · filed 2025-04-02 | 3.17M EUR 20-F · filed 2023-04-24 | |
| 2022-06-30 | 1.36M EUR 6-K · filed 2023-09-26 | ||
| 2021-12-31 | 3.20M EUR 20-F · filed 2024-04-24 | ||
| 2021-06-30 | 1.40M EUR 6-K · filed 2022-09-28 | ||
| 2020-12-31 | 2.92M EUR 20-F · filed 2023-04-24 | ||
| 2020-06-30 | 1.54M EUR 6-K · filed 2021-09-08 | ||
| 2019-12-31 | 4.32M EUR 20-F · filed 2022-04-08 | ||
| 2018-12-31 | 1.87M EUR 20-F/A · filed 2021-04-08 |